Exenatide Use in the Management of Type 2 Diabetes Mellitus
Exenatide is a GLP-1 (glucagon-like peptide-1) agonist that has been approved in the UK for use in the management of Type 2 Diabetes Mellitus (T2DM) since 2006. It acts by increasing glucose-induced insulin release and by reducing glucagon secretion postprandially. It therefore increases insulin sec...
Main Authors: | Angelos Kyriacou, Abu Baker Ahmed |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2010-08-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | http://www.mdpi.com/1424-8247/3/8/2554/ |
Similar Items
-
New indications for exenatide therapy of type 2 diabetes mellitus
by: Olga Konstantinovna Vikulova, et al.
Published: (2010-09-01) -
Pharmalogical effects and results of clinical trials of the first incretinomimetic exenatide
by: Alexander Sergeevich Ametov, et al.
Published: (2011-09-01) -
Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
by: Seewoodhary J, et al.
Published: (2010-05-01) -
CARDIOPRODUCTIVE EFFECTS OF EXXENATE AMID AND VILDAGLIPTIN INCRETIN MIMETICS IN DOXYRUBRICINE CARDIOMYOPATHY MODELING
by: A. P. TARASOVА, et al.
Published: (2017-09-01) -
Exenatide improves hepatocyte insulin resistance induced by different regional adipose tissue
by: Chuanmin Bai, et al.
Published: (2022-09-01)